Medulloblastoma and neuroblastoma account for >30% of childhood cancer deaths and are major challenges in the management of children with cancer. Our team of researchers aim to understand the molecular mechanisms of tumour development by using genomic, cell biology and model-system approaches. This research will lead to new personalised or patient-centred therapies with increased survival and lower therapy-associated late effects.
At all levels, our research goals are supported by close integration with National and International clinical networks and engagement in local, National and International research collaborations.
Research activities in paediatric nervous system tumours include:
The clinical, histological and molecular characterisation of medulloblastoma represents an important area of research to improve disease subclassification and the identification of genes critical to disease development. There has been a discovery of molecular medulloblastoma subgroups with distinct clinical features and outcomes. Indeed, biological and histological markers have been identified and validated for risk-stratification of medulloblastoma patients.
This research will be used to facilitate patient stratification in pan-European clinical trials, and early-phase clinical trials of new therapeutic strategies.
Four interrelated themes: